Legacy MEDSearch

AUGUST 25, 2022

Early non-randomized European studies have suggested that this leads to reduced incidence of coronary microvascular obstruction (MVO) [3,4] and smaller infarct size, which are both strongly correlated to improvement in heart failure hospitalizations and reduced mortality following primary PCI [5]. said Olivier Delporte, CEO.

Medical 52

Medical FDA Recruitment Pharmacology 52

European Pharmaceutical Review

MAY 2, 2023

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 1,2 In the EU, an estimated 2.7 Available from: [link] Worldwide cancer statistics [Internet].

Patients 98

Patients Medicine Marketing Medical 98

European Pharmaceutical Review

SEPTEMBER 29, 2022

Most ISRs were mild to moderate in severity and none lead to premature discontinuation from the study. There were no life threatening TEAEs, TEAEs leading to premature discontinuation of study, serious adverse events (SAEs) or deaths. PPD is an extremely common psychological condition affecting women after labour.

Pharmacology 88

Pharmacology Leads Patients Management 88

pharmaphorum

JANUARY 16, 2023

Last year, IQVIA predicted that 2022 would be the crunch year for Alzheimer’s therapies: it is with a sense of déjà vu that the exact same prediction is contemplated for 2023. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast. Innovation will power the market.

FDA 88

FDA Healthcare Healthcare Medicine 88

Map My Customers

MARCH 31, 2022

As a pharmaceutical sales rep, there are appointments and meetings with doctors and professionals that need to stay up to date with the latest pharmacology treatment options for their patients. Pharmaceutical sales representatives will be the face of the company for drug and treatment manufacturers.

Medical sales reps 52

Medical sales reps Medical sales Sales Medical 52

European Pharmaceutical Review

JANUARY 18, 2024

billion in 2022 to $4.1 percent between 2022 and 2032. percent between 2022 and 2032. GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. percent from $3.2 billion in 2032. million in sales by 2032.

Marketing 88

Marketing Sales Pharmacology Pharma 88

Pharmaceutical Technology

FEBRUARY 8, 2023

In 2022, 54% of FDA new drug approvals were for rare diseases , a significant increase in proportion of approvals in the recent years. Blank acknowledged that in many cases, an exclusively paediatric patient population could lead to difficulties with drawing consent for early phase trials.

FDA 105

FDA Pharmacology Patients Pharmaceutical 105

Pharmaceutical Technology

NOVEMBER 3, 2022

There, Boehringer had earlier warned of the impending alteplase shortage in April 2022. This is due to aging populations around the world, which leads to an increased risk of such conditions, explains Craig Beavers, PhD, assistant professor at the University of Kentucky’s College of Pharmacy in Lexington.

Medicine 111

Medicine Manufacturing Pharmacology Healthcare 111

European Pharmaceutical Review

DECEMBER 11, 2023

Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities. Research advances are also helping us learn more about how RNA is processed, potentially leading to new strategies to alter dysfunctional RNA. cited 2023July].

Pharmacology 81

Pharmacology Safety Engineering Medical 81

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. 2022 Alzheimer’s Association International Conference. months for donanemab.

Food and Drug Administration 75

Food and Drug Administration Safety Patients Leads 75

Pharmaceutical Technology

AUGUST 8, 2022

The digital pill, now marketed by Otsuka Pharmaceuticals, is forecasted to make $27 million in sales in 2022, as per GlobalData. These days, he is leading trials involving a system developed by the digital health company etectRx (pronounced as e-tect-are-ex), which works with investigators who can use such real-time data.

Food and Drug Administration 122

Food and Drug Administration FDA Medicine Patients 122